Titan Pharmaceuticals is effectively a shell company with no active operations, products, or employees. Titan previously developed drug delivery products using its ProNeura platform — a subdermal implant technology designed to deliver drugs at a steady rate over time. Its only commercialized product was Probuphine, a buprenorphine implant for opioid use disorder. Titan sold the ProNeura assets, including Probuphine, to Fedson in September 2023 for up to $2M plus potential milestones, exiting its core business entirely. Titan retains the right to receive up to $50M in milestone payments and certain royalties on future ProNeura net sales, though these are contingent on Fedson's commercial success. Today, Titan's sole focus is completing a reverse merger with TalenTec, a Malaysian company, which would result in Titan becoming a wholly owned subsidiary of a new Cayman Islands holding company called BSKE, to be listed on Nasdaq. The transaction requires Titan stockholder approval and Nasdaq listing approval for BSKE. Titan has no revenue, is burning through cash reserves, and has undergone significant management turnover, with four CEOs in roughly two years. TalenTec's underlying business is not described in Titan's filings.